Axsome Therapeutics (AXSM) Competitors $107.78 -1.97 (-1.79%) As of 02:15 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AXSM vs. ONC, BNTX, TEVA, SMMT, ITCI, MRNA, GMAB, RDY, VTRS, and ASNDShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Moderna (MRNA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Axsome Therapeutics vs. Beigene BioNTech Teva Pharmaceutical Industries Summit Therapeutics Intra-Cellular Therapies Moderna Genmab A/S Dr. Reddy's Laboratories Viatris Ascendis Pharma A/S Beigene (NASDAQ:ONC) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, community ranking, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment. Which has more risk and volatility, ONC or AXSM? Beigene has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Does the media refer more to ONC or AXSM? In the previous week, Axsome Therapeutics had 16 more articles in the media than Beigene. MarketBeat recorded 23 mentions for Axsome Therapeutics and 7 mentions for Beigene. Beigene's average media sentiment score of 0.67 beat Axsome Therapeutics' score of 0.38 indicating that Beigene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beigene 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Do analysts rate ONC or AXSM? Beigene currently has a consensus target price of $310.00, suggesting a potential upside of 17.19%. Axsome Therapeutics has a consensus target price of $167.64, suggesting a potential upside of 55.54%. Given Axsome Therapeutics' higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Beigene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beigene 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, ONC or AXSM? Axsome Therapeutics has lower revenue, but higher earnings than Beigene. Beigene is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeigene$3.81B6.85-$881.71M-$6.14-43.08Axsome Therapeutics$385.69M13.63-$287.22M-$5.99-17.99 Does the MarketBeat Community prefer ONC or AXSM? Axsome Therapeutics received 475 more outperform votes than Beigene when rated by MarketBeat users. Likewise, 70.50% of users gave Axsome Therapeutics an outperform vote while only 60.00% of users gave Beigene an outperform vote. CompanyUnderperformOutperformBeigeneOutperform Votes360.00% Underperform Votes240.00% Axsome TherapeuticsOutperform Votes47870.50% Underperform Votes20029.50% Is ONC or AXSM more profitable? Beigene has a net margin of -25.94% compared to Axsome Therapeutics' net margin of -74.47%. Beigene's return on equity of -25.12% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beigene-25.94% -25.12% -14.95% Axsome Therapeutics -74.47%-223.51%-39.88% Do insiders and institutionals have more ownership in ONC or AXSM? 48.5% of Beigene shares are held by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are held by institutional investors. 7.4% of Beigene shares are held by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAxsome Therapeutics beats Beigene on 12 of the 17 factors compared between the two stocks. Remove Ads Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.26B$6.77B$5.58B$7.57BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-17.997.0522.9818.19Price / Sales13.63200.85362.8486.44Price / CashN/A65.6738.1634.64Price / Book91.345.966.534.03Net Income-$287.22M$142.59M$3.21B$247.18M7 Day Performance-11.49%-8.48%-5.84%-5.61%1 Month Performance-15.23%-9.49%-0.12%-6.72%1 Year Performance46.64%-14.57%6.42%-3.53% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.6912 of 5 stars$107.45-2.1%$167.64+56.0%+47.2%$5.24B$385.69M-17.94380Analyst ForecastShort Interest ↓News CoverageGap DownONCBeigene1.3863 of 5 stars$254.16+0.9%$310.00+22.0%N/A$25.00B$3.81B-30.8410,600Gap UpBNTXBioNTech2.4719 of 5 stars$100.53+5.4%$143.73+43.0%+2.0%$24.11B$2.75B-47.846,133Analyst ForecastGap DownTEVATeva Pharmaceutical Industries2.3744 of 5 stars$16.18+0.5%$23.43+44.8%+10.5%$18.34B$16.54B-11.1536,800Short Interest ↑Gap DownSMMTSummit Therapeutics2.9997 of 5 stars$20.64+4.5%$34.11+65.3%+431.4%$15.16B$700,000.00-73.37110Gap DownITCIIntra-Cellular Therapies3.6007 of 5 stars$131.70+0.0%$106.08-19.5%+97.9%$14.00B$680.50M-151.37560Analyst ForecastNews CoveragePositive NewsMRNAModerna4.3532 of 5 stars$34.34+5.1%$59.00+71.8%-73.2%$13.24B$3.20B-3.703,900Gap DownGMABGenmab A/S3.857 of 5 stars$19.29-2.4%$41.33+114.3%-37.2%$12.76B$21.53B11.082,204Analyst DowngradeShort Interest ↑RDYDr. Reddy's Laboratories3.3427 of 5 stars$13.710.0%$17.00+24.0%-10.3%$11.44B$311.31B21.8224,800Positive NewsVTRSViatris2.6949 of 5 stars$9.27+1.3%$10.50+13.3%-27.5%$11.05B$14.74B-12.5137,000ASNDAscendis Pharma A/S3.1273 of 5 stars$168.65+1.6%$204.64+21.3%+4.0%$10.21B$363.64M-23.701,017Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies ONC Alternatives BNTX Alternatives TEVA Alternatives SMMT Alternatives ITCI Alternatives MRNA Alternatives GMAB Alternatives RDY Alternatives VTRS Alternatives ASND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AXSM) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AXSM Stock Free AXSM Stock Alerts